PROCRITline.com - Online Reimbursement & Health Care Resources

Portal Home

For reimbursement information regarding other Centocor Ortho Biotech Inc. products, please click here.

PROCRITline.com Reimbursement Excellence

Online Reimbursement & Health Care Resources

Please see full Prescribing Information, including Boxed WARNINGS, for PROCRIT^® (Epoetin alfa)

Full Printable Version

Main Page

Payor Directories

Medicare Part A MAC and Fiscal Intermediary Sites

Medicare Part B MAC and Carrier Sites

Private Insurer Sites

Government Sites

State Departments of Insurance Sites

Practice Management Support Sites

Medicaid Sites

ADAP Sites

Managed Care Related Sites

Medical and Journal Sites

State Oncology Societies

Patient Advocacy and Support Group Sites

	General
	Oncology
	Nephrology
	Immunology

Consumer Sites

Useful Search Engines

Combined Listing of All Books

KEY LINKS

Online Reimbursement & Health Care Resources

Patient Advocacy and Support Group Sites

PREVIOUS | NEXT

General

Oncology

Nephrology

Immunology

Access2Wellness

American Association of Retired Persons

Association of Clinicians for the Underserved

National Black Nurses Association

National Conference of State Legislatures

National Senior Citizens Law Center

National Patient Advocate Foundation

Patient Advocate Foundation

PREVIOUS | NEXT

Important Safety Information for PROCRIT^® (Epoetin alfa)

WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE

Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious cardiovascular events, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target hemoglobin levels of 13 g/dL and above.

Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: Table 1).

To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusion.

Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense PROCRIT^® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.

ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

Discontinue following the completion of a chemotherapy course.

Perisurgery: PROCRIT^® (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.

(See WARNINGS: Increased Mortality, Serious Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Please see full Prescribing Information, including Boxed WARNINGS for PROCRIT^® (Epoetin alfa)

Medication Guide for PROCRIT^®
Please read the Medication Guide for PROCRIT^® and discuss with your doctor.

Patient Instructions for Use
Instructions if you or your caregiver has been trained to give PROCRIT^® injections at home.